The success Gilead has had with Letairis at the FDA sharply contrasts with a rival compound by Encysive Pharmaceuticals
How well ambrisentan competes with Tracleer is still up in the air. Worldwide Tracleer sales were more than $700 million last year. Ambrisentan was approved to treat earlier-stage PAH patients with what is known as the World Health Organization class II or III symptoms, whereas Tracleer is approved to treat patients with the worse class III and IV symptoms (and is in testing for early-stage sufferers as well).
Ambrisentan may have some important safety advantages over Tracleer, with a lower incidence of liver-related adverse events in its clinical studies. But the drug also suffers from a very strict black box warning. Tracleer also carries a black box warning, and requires a patient access program.
After paying $2.5 billion to acquire Myogen last year, Gilead will now start to reap the rewards from this buyout, with sales of Letairis set to begin next week. With the release of positive clinical trial results for several pipeline compounds in the past two months and now the Letairis regulatory success, Gilead has had a strong first half of 2007.
Encysive is a Rule Breakers recommendation. You can check out all our recommendations as well as get access to our message boards and exclusive content with a 30-day free trial.
More from The Motley Fool
Is Gilead Sciences, Inc. a Buy in 2018?
Focus on the future rather than the past for this big biotech.
2017 Was a Year to Forget for Gilead Sciences, Inc., but This Year Could Be Better
In the short term, the biotech's success is still tied to its HIV and HCV franchises, but keep an eye on the pipeline.
5 Ways Gilead Sciences Plans to Return to Growth
Gilead's CEO reveals the biotech's game plan at the J.P. Morgan Healthcare Conference.